JW Pharmaceutical (KRX: 001060) announced that its gout treatment candidate Epaminurad (URC102) met the primary efficacy endpoint in a multinational ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE